Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiome Transplantation for Constipation and Bloating in Systemic Sclerosis
NCT06827977Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc), constipation and abdominal bloating comparing PRIM-DJ2727 with Placebo (2 arms). Primary endpoints: University of California, Los Angeles Gastrointestinal Tract Questionnaire, version 2.0 total score, Pelvic Floor Distress Inventory Questionnaire-20 summary score and 7 more. Started Mar 2025; status: recruiting.
02
Drugs
PRIM-DJ2727
03
Conditions
systemic sclerosis (SSc)constipationabdominal bloating
Beyond the preview
Go deeper on NCT06827977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827977.